Kaleido Biosciences’s Return On Capital Employed Insights
According to Benzinga Pro data, during Q3, Kaleido Biosciences (NASDAQ:KLDO) posted sales of $104.00 thousand. Earnings were up 3.42%, but Kaleido Biosciences still reported an overall loss of $22.41 million.
Morgan Stanley Downgrades Kaleido Biosciences to Underweight, Announces $3 Price Target
Morgan Stanley analyst Matthew Harrison downgrades Kaleido Biosciences (NASDAQ:KLDO) from Equal-Weight to Underweight and announces $3 price target.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
36 Biggest Movers From Yesterday
Gainers
Bit Digital, Inc. (NASDAQ: BTBT) shares climbed 36.4% to settle at $10.35 on Tuesday amid an increase in the price of Bitcoin and Ethereum.
Why Did Kaleido Shares Plunge 10% On Tuesday?
Kaleido Biosciences Inc (NASDAQ:KLDO) announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT), in…